Medicxi

Medicxi is a premier European venture capital firm specializing in life sciences, with a focus on drug discovery and therapeutic development. Established in 2016 by the former life sciences team of Index Ventures, the firm has raised over €1 billion across various funds. Medicxi’s flagship funds, such as Medicxi III (€400 million), invest in both early and late-stage biopharma companies. Notable investments include Genmab, Micromet (acquired by Amgen), and Minerva Neurosciences. Medicxi's investment strategy is centered around its "asset-centric" approach, where the firm invests in companies with strong clinical proof-of-concept that address clear unmet medical needs. Their investments typically range between €10 million and €25 million, supporting companies through key phases like clinical development and regulatory approval​. The firm partners closely with major pharmaceutical players such as Novartis, Johnson & Johnson, and GlaxoSmithKline, which provides strategic backing for its portfolio companies​. Headquartered in London, Geneva, and Jersey, Medicxi has become a leading name in European biotech, with a strong emphasis on translating scientific innovation into commercially viable drugs. Their portfolio spans across the full healthcare continuum, from early discovery to late-stage clinical assets, giving them a unique position in Europe’s life sciences ecosystem. Through its deep ties to industry leaders and a robust scientific advisory board, Medicxi continues to drive the next generation of breakthrough therapeutics​.